Martin Andersson - Sprint Bioscience Founder and Director of Discovery Projects
| SPRINT Stock | SEK 1.82 0.02 1.09% |
Director
Dr. Martin Andersson, Ph.D. is Head of Biology at Sprint Bioscience AB. He is one of the Founders of the Company. He was employed at the Company since 2009. He holds a Doctorate in Philosophy degree in Biochemistry from Stockholms universitet. Between 2001 and 2003 he worked to establish a lab for highthroughput protein production and structure determination, pioneering the application of these technologies in a highthroughput format in Europe. In 2003 he joined AstraZeneca working at the AstraZeneca biotech laboratory, a centre of excellence in production of target proteins for use in internal drug discovery projects. He has experience in project management and resource management and during the last years at AstraZeneca Martin worked strategically representing a set of specialized capabilities towards customers in one of the research areas within AstraZeneca. Martin is the coauthor of 9 peerreviewed publications.
| Age | 52 |
| Phone | 46 84 11 44 55 |
| Web | https://www.sprintbioscience.com |
Sprint Bioscience Management Efficiency
The company has return on total asset (ROA) of (0.5879) % which means that it has lost $0.5879 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.0926) %, meaning that it generated substantial loss on money invested by shareholders. Sprint Bioscience's management efficiency ratios could be used to measure how well Sprint Bioscience manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 6 records | DIRECTOR Age | ||
| Thoas Fioretos | Cantargia AB | 53 | |
| Patricia Delaite | Cantargia AB | 53 | |
| Gunnar Telhammar | Xintela AB | 62 | |
| Karin Leandersson | Cantargia AB | 43 | |
| Anders MartinLof | Cantargia AB | 48 | |
| Claus Andersson | Cantargia AB | 51 | |
Management Performance
| Return On Equity | -1.09 | |||
| Return On Asset | -0.59 |
Sprint Bioscience Leadership Team
Elected by the shareholders, the Sprint Bioscience's board of directors comprises two types of representatives: Sprint Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sprint. The board's role is to monitor Sprint Bioscience's management team and ensure that shareholders' interests are well served. Sprint Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sprint Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
| AnneMarie Wenthzel, Director of Sales and Marketing | ||
| Martin Andersson, Founder and Director of Discovery Projects | ||
| Pr Nordlund, Founder and Director | ||
| Jessica MSc, Founder, Director of Medicinal Chemistry and Director | ||
| Mathias Skalmstad, Chief Officer | ||
| Kenth Hallberg, Founder and Director of Structural Chemistry | ||
| Prof MBA, Chief Officer |
Sprint Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sprint Bioscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.09 | |||
| Return On Asset | -0.59 | |||
| Operating Margin | (76.00) % | |||
| Current Valuation | 24.98 M | |||
| Shares Outstanding | 69.8 M | |||
| Shares Owned By Insiders | 35.31 % | |||
| Shares Owned By Institutions | 2.59 % | |||
| Price To Earning | 32.79 X | |||
| Price To Book | 2.61 X | |||
| Price To Sales | 27.09 X |
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Sprint Stock
Sprint Bioscience financial ratios help investors to determine whether Sprint Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sprint with respect to the benefits of owning Sprint Bioscience security.